F5 Names Michael Montoya Chief Technology Operations Officer-February 2024-www.financetom.com

F5 Names Michael Montoya Chief Technology Operations Officer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

F5 Names Michael Montoya Chief Technology Operations Officer

Oct 23, 2025 6:52 AM

09:43 AM EDT, 10/23/2025 (MT Newswires) -- F5 (FFIV) said Thursday it has named Michael Montoya its chief technology operations officer.

Montoya has transitioned from his position on the company's board, F5 said.

Price: 298.80, Change: +0.96, Percent Change: +0.32

Previous page： -- Open Text Brief: Raises Fiscal 2025 Margin Targets Next page： --Amazon.com Guides For Q3 Sales of $154-$158.5 Billion, vs CIQ Analyst Consensus of $158.3 Billion

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

-- Open Text Brief: Raises Fiscal 2025 Margin Targets

Aug 1, 2024

04:01 PM EDT, 08/01/2024 (MT Newswires) -- Price: 42.27, Change: -1.25, Percent Change: -2.87 ...

--Amazon.com Guides For Q3 Sales of $154-$158.5 Billion, vs CIQ Analyst Consensus of $158.3 Billion

Aug 1, 2024

04:02 PM EDT, 08/01/2024 (MT Newswires) -- Price: 175.08, Change: -8.99, Percent Change: -4.88 ...

Why Eaton Corporation Shares Are Moving After Q2 Results

Aug 1, 2024

Eaton Corporation PLC ( ETN ) shares are trading lower by 2.9% to $295.98 during Thursday’s session after the company reported second-quarter financial results. What Happened: For the second quarter of 2024, Eaton reported an adjusted EPS of $2.73, which exceeded the estimated $2.61. The company's sales for the quarter were $6.4 billion, surpassing the $6.341 billion estimate. Eaton projected...

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments

Aug 1, 2024

Aug 1 (Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue in the range of $10.65 to $10.85 billion, compared to its prior forecast of $10.55 to $10.75 billion. The company said that the forecast includes expectations for...